Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 298

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

GRIN2A mutation and early‐onset epileptic encephalopathy: personalized therapy with memantine

Open access
Pierson, Tyler Mark, Yuan, Hongjie, Marsh, Eric D., Fuentes‐Fajardo, Karin, Adams, David R., Markello, Thomas, Golas, Gretchen, Simeonov, Dimitre R., Holloman, Conisha, Tankovic, Anel, Karamchandani, Manish M., Schreiber, John M., Mullikin, James C., Tifft, Cynthia J., Toro, Camilo, Boerkoel, Cornelius F., Traynelis, Stephen F., Gahl, William A.·2014·Annals of Clinical and Translational Neurology

Abstract

Objective Early-onset epileptic encephalopathies have been associated with de novo mutations of numerous ion channel genes. We employed techniques of modern translational medicine to identify a disease-causing mutation, analyze its altered behavior, and screen for therapeutic compounds to treat the proband. Methods Three modern translational medicine tools were utilized: (1) high-throughput sequencing technology to identify a novel de novo mutation; (2) in vitro expression and electrophysiology assays to confirm the variant protein's dysfunction; and (3) screening of existing drug libraries to identify potential therapeutic compounds. Results A de novo GRIN2A missense mutation (c.2434C>A; p.L812M) increased the charge transfer mediated by N-methyl-D-aspartate receptors (NMDAs) containing the mutant GluN2A-L812M subunit. In vitro analysis with NMDA receptor blockers indicated that GLuN2A-L812M-containing NMDARs retained their sensitivity to the use-dependent channel blocker memantine; while screening of a previously reported GRIN2A mutation (N615K) with these compounds produced contrasting results. Consistent with these data, adjunct memantine therapy reduced our proband's seizure burden. Interpretation This case exemplifies the potential for personalized genomics and therapeutics to be utilized for the early diagnosis and treatment of infantile-onset neurological disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/acn3.39

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 298

Metadata

Authors
Pierson, T. M., Yuan, H., Marsh, E. D., Fuentes‐Fajardo, K., Adams, D. R., Markello, T., Golas, G., Simeonov, D. R., Holloman, C., Tankovic, A., Karamchandani, M. M., Schreiber, J. M., Mullikin, J. C., Tifft, C. J., Toro, C., Boerkoel, C. F., Traynelis, S. F., & Gahl, W. A.
Venue
Annals of Clinical and Translational Neurology
Publisher
Wiley
Published
2014-03
Volume
1
Issue
3
Pages
190-198
ISSN
2328-9503 (ISSN-L)
OpenAlex
W1987093811
Cited by
298
References
28
FWCI
17.07
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GRIN2A mutation and early‐onset epileptic encephalopathy: personalized therapy with memantine. https://app.cochat.ai/papers/10.1002/acn3.39
The paper
Pierson, T. M., Yuan, H., Marsh, E. D., Fuentes‐Fajardo, K., Adams, D. R., Markello, T., Golas, G., Simeonov, D. R., Holloman, C., Tankovic, A., Karamchandani, M. M., Schreiber, J. M., Mullikin, J. C., Tifft, C. J., Toro, C., Boerkoel, C. F., Traynelis, S. F., & Gahl, W. A. (2014). GRIN2A mutation and early‐onset epileptic encephalopathy: personalized therapy with memantine. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.39

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.